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1.

ABSTRACT

To investigate whether the immunosuppressive neuropeptide
calcitonin gene related peptide (CGRP) was a potential candidate for
tissue-specific

gene

therapy,

we

engineered

Non-Obese

Diabetic

(NOD) mice to produce CGRP in beta cells by placing the modified
calcitonin gene under the control of the rat insulin promoter.

CGRP

inhibits the production of cytokines by Thl cells which have been
implicated in the pathogenesis of type I diabetes.
positive

mouse

lines

were

obtained,

two

Three transgene

of

which

immunoreactive CGRP in beta cells (NOD-CGRP mice).

express

Isolated islets

from one of these two transgene positive founders produced active
CGRP while

islets from

transgene

production of CGRP by beta cells
reduces

its

incidence

by

63

%

negative
prevents
in

female

mice
IDDM
NOD

did

not.

The

in male,
mice.

and
This

immunosuppressive effect of CGRP is due to a local effect and not a
systemic

effect

of CGRP

on peripheral

lymphoid

organs

as no

difference was detected between NOD-CGRP and NOD mice lymph
node, spleen and thymus cells by either fluorescence-activated cell
sorter analysis or proliferative response to stimulation by antigen,
alloantigen or anti-CD3.

CGRP partially prevented peri-insulitis in

NOD-CGRP mice whose lymphoid cell composition was similar to that
of NOD mice, further suggesting the local immunoregulatory effect of

CGRP.

These

data suggest that CGRP is a potential

therapeutic

molecule to prevent or treat diabetes and possibly other diseases and
conditions in which
suggest

that

immune

endogenous

cells

CGRP

are involved.
concentrated

These
in

data also

sensory

nerve

endings may regulate locally in tissues the immune response, further
strengthening the importance of the functional neuro-immune link.
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2. INTRODUCTION

2.1 Establishment of Reference Point

BALANCE +

SIMPLICITY = EXISTENCE

At a very basic level to defend

a thesis, a reference

point is

required. As odd as it may seem. I have chosen the above equation as
that reference point.

.Arguably the goal of life at a rudimentary level

is existence.

If this is the case, then I believe that the requirements

of existence

from

simplicity.

an evolutionary

point

of view are

balance

and

During existence an organism is subjected primarily to

two main forces: environmental and evolutionary, which are one and
the

same

but

on

a different

time

scale.

Environment

mandates

balance and evolution mandates simplicity.
Balance
extremes,

implies

between

some

arbitrary

high or low,

midpoint

between

much

in

between

or little.

two

Further

implication is that an organism that is in balance can exist within the
range of the two extremes and, if subjected to environmental forces,
can

shift

its

accordingly.

balance

in

one

direction

or

the

other

to

adapt

The time scale between the stimulus (an environmental

force) and the response (shift in balance) is small.

4

Evolution, on the other hand, exerts its influence on a much
larger

time

functional

scale.

Evolutionary

efficiency

change

(adaptedness)

of

is

determined

by

the

organism

in

its

the

environment1. Webster's dictionary defines efficiency as an “ability to
produce a desired effect . . . with a minimum of effort, expense, or
waste.”

Any

given

organism

functions in order to survive.
must be performed
waste.

with

must

perform

numerous

biological

Each and every one of these functions

the least amount of effort,

expense

and

If ten competitors involved in a contest were asked to design

a system to perform a certain function,

surely the simplest design

with the least number of steps would win. unless a different design,
even if it involved a few more steps, could be shown to perform that
function

much

better.

Over

billions

of years

every

evolution has been put to the same test by nature.
which some may egocentricallv
evolutionary
However,
simpler

design,

may

it is a large

most efficient manner.

seem

system

subsystems each

believe
quite

complex

at

first

of indefinite

its assigned

of the

A human being,

to be the epitome

comprised

performing

step

of the
glance.

number

function

in

of
the

It is of vital importance to realize that this is

not a system whose mechanism can be explained by linear dynamics,
rather

it is a system

which

at every

step

comprised
simply

of extensive

self-regulate

nonlinear

through

networks

a multitude

of

5

feedback mechanisms. Finally, to paraphrase a well known saying,
evolution is the survival of the fittest and the simplest.
Most if not all of science is the study of nature and of existence
in particular. Through the ages nature has selected to travel down
the path of simplicity and balance. Consequently, if we are to unravel
and explain the “way of nature," then we must abide by its rules and
follow the same path it has taken. Following the gathering of data,
teleologically

we

must

strive

to

formulate

theory consistent with all that is known

the

simplest

possible

and with balance

as its

fundamental tenet.

2.2 Autoimmune Disease

Understanding complex biological systems is a great challenge.
Every discovery represents

an individual piece

needs to be arranged in its respective

of information that

place without knowing with

certainty how the pieces interrelate. With this in mind theories are
introduced as to what the overall picture may look like and how the
individual pieces fit together.
like

in a jigsaw puzzle,

This is an essential step because just

even if all the

pieces

are

present,

if an

incorrect picture is used as a guide, the puzzle cannot be solved.
Various

theories

of

how

the

immune

system

functions

physiological setting have evolved within the past century.

in

a

■
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We are taught that immunology is the science

of self-nonself

discrimination2. Yet the understanding of how the boundary between
self and nonself is established is far from complete. What is certain is
that

under

“normal”

autoimmune disease,
place

and

self is

conditions
a breach

no

longer

self

in the

tolerated.

is

tolerated

while

in

self-nonself boundary
To

a great

an

takes

extent

as

a

consequence of our incomplete understanding of immunophysiology,
the definitive mechanism of autoimmue disease remains a mystery.
However, enormous amount of work has been done in this field in the
past half century.
Burnet, in 1959,

proposed

the “clonal

selection

theory”

and

according to this theory the immune system during its development
consists of ceils that possess within their repertoire
are

potentially

self reactive.

Self tolerance

is

receptors

established

that
by

a

process of thymic deletion of self reactive T-cells, while cells that are
reactive to foreign antigens are spared3.
T-cell

deletion has been confirmed

healthy

states only immune

cells

This process of self-reactive

as recently
that are

as

19874.

capable

During

of potentially

binding foreign antigens exist and recognition of self is nonexistent.
Autoimmune disease is bom when, for various reasons or purely by
accident, elements of the immune system appear that recognize self
and

embark

autoimmune

on

a journey

of self destruction".

disease must result whenever

a cell

In other
clone

words

that

was

7

eliminated during thymic education enjoys a reincarnation of sorts.
In contradiction to this theory, various authors have reported

that

both T and B cells capable of autoimmune disease induction have
been

detected

individuals67.

in

the

Recently,

peripheral
Katz

and

lymphoid
his

tissues

colleagues

of

healthy

looked

at

the

tolerance status of T cells bearing the transgenic, pathogenic T cell
receptor

(TCR)

for self antigen
(IDDM)

responsible
Non-Obese

insulin-dependent

diabetis

mellitus

model8.

T cells with the transgenic TCR were not deleted as would

have been predicted

of the

for

by the clonal

Diabetic(NOD)

selection

theory.

mouse

In fact,

they

interacted with self-antigens both in vitro and in vivo, and induced
IDDM in these mice.
Other observations,

which

also contradicted

clonal

selection

theory, have led to the formation of alternative theories including the
“idiotypic network theory.”

This theory is based on the hypothesis

that the immune system consists of both idiotypic and anti-idiotypic
entities

which

homeostasis.

through

their

Autoimmune

disease

aberrant and disproportionate
roots of this theory

can

be

interactions
results

proliferation
traced

back

establish
as

a

immunologic

consequence

of certain clones.
to Jerne

who

in

of

The
1974

proposed that self-reactivity is a normal component of the immune
system whose major function is to maintain internal macromolecular
homeostasis rather than protect the host from external invasion4.

Barnett in early

1980's proposed

the "primary

lesion theory"

which suggests that autoimmunity is not itself a distinct entity, but a
physiological

response

to

sustained

antigen

overproduction

in

diseased tissue, and fundamentally no different from the response to
foreign antigen10.
event

in

The phenomenon referred to as the “precipitating

autoimmunity”

is

viewed

as

a

primary

lesion,

whose

continued presence is necessary to drive and sustain the response
conventionally

referred

to as autoimmunity.

Those

who

develop

clinical disease are regarded as high responders to critical antigens
generated in excess by the primary lesion.
determined

by immune

response,

High responder status is

HLA-linked,

genotype.

The

HLA

class II (D region genes) are closely linked to immune reponse genes
which control the response of specific clones".

Thus, one strain of

animal may fail to respond to an antigenic shape to which another
strain of the same species reacts strongly.

HLA phenotype is a good

marker for such differences, and what applies to exogenous antigens
also applies to autoantigens, but over a range of reactivity normally
consistent with health. Barnett suggests that in type

1 diabetes,

a

primary

rise in j3-cell

expansion

of

specific

and appropriate

antigen

load

clones.

is met with

The

extent

an

of clonal

relative to the antigen overload is HLA determined.

expansion

Effector immune

cells cannot distinguish diseased from healthy j^-ceils,

and in the

minority of those with the primary lesion who are high responders,
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their greater

number leads to inexorable

destruction

of all j3-cell

tissue.
Since cell products in excess are toxic and biologically active
substances

can

cause

various

clinical

syndromes,

Barnett

hypothesizes that “physiologic” autoimmunity may act as a defence
mechanism in the face of antigen excess not only by neutralizing
their

biological

or

toxic

effect

on

contact

alternative pathway for their clearance.

but

by

providing

an

Thus, although autoimmune

disease may sometimes lead to organ destruction and death of the
individual, it may have an advantageous defensive function for the
species.
All three of the theories discussed above attempt to explain the
process

of tolerance.

A large

body of evidence

supports and contradicts these theories.
clonal selection theory,

exists

that

both

Though the simplest,

the

because of its suggestion that autoreactive

cells are categorically deleted during thymic education, is certainly
lacking

in balance.

The idiotypic

network

theory,

though

more

complex, incorporates balance as its fundamental building block.
fact,

it goes hand in

hand

with

the

primary

lesion

theory.

In
As

idiotypic network theory suggests the immune system is utilized by
the organism
maintain

not

internal

only

to

ward

homeostasis.

network disproportionately

off foreign
When

proliferate,

invasion,

certain

clones

but

also

within

to
the

they do so as a result of a

10

certain precipitating event.
cornerstone
idiotypic

of the

This precipitating event is viewed as the

primary

lesion

theory.

Taken

together,

network theory and the primary lesion theory

the

suggest a

mechanism of tolerance and breakdown thereof, that lies within the
realm of both simplicity and balance.

2.3 Diabetes Mellitus
2.3.1 Overview of Diabetes
Diabetes

is the name

arising from hyperglycemia.

given to a constellation

of symptoms

The disease can occur as a result of

specific secondary causes ranging from iron overload of beta cells
seen in hemochromatosis to insulin receptor defects.

However, vast

majority of patients with diabetes do not have a specific identifiable
defect and are said to have idiopathic diabetes.
It was little more than 20 years ago that diabetes was thought
of as a single disease with more or less severe manifestations. The
clinical distinction of more severe, ketosis-prone, insulin-dependent
type (IDDM)

and the more

common,

non-insulin-dependent

(NIDDM) had been recognized by clinicians for many years.

type

In 1951,

Lawrence and his colleagues proposed that diabetes could be divided
into two main types: “[1] Those who are probably not insulin-deficient
and [2] those who certainly are.” This observation was based on the
studies that they

performed

on

10

diabetics:

five

young

ketotic

patients who they believed had insulin deficiency and five obese non-

ketotic
than

patients in whom diabetes was attributed

insulin

estimated

deficiency12.

by

injecting

Insulin

the

level

patient’s

in

plasma

hypophysectomized and adrenalectomized rats.

to factors

these
into

other

patients

was

alloxan-diabetic

The fall in the blood

glucose of the rats after 1 hour correlated with the amount of insulin.
The five patients with ketosis had no insulin unlike

the five non¬

ketotic patients who did.
The first suggestion of significant difference between
types diabetes came from identical twin studies.
concordance

was

nearly

one

hundred

the two

It w'as found that

percent

in

non-insulin

dependent diabetics, but less than fifty percent in insulin dependent
diabetics13. The

proof of fundamental

difference

between

the

two

types of diabetes came from a study published in 1974 that showed a
strong association between certain HLA types and IDDM, but no such
association was observed

in NIDDM14.

The

authors believed

that

IDDM had an autoimmune basis and that viruses were also involved
in the disease

pathogenesis as was suggested by Gamble and his

colleagues in earlier studies15.

In that same year Bottazzo reported

antibodies toward normal pancreatic islets cells in 13 patients with
multiendocrine

deficiencies16.

All

these

observations

concordance with reports made in 1950’s and 60’s

were

regarding

in
the

presence of the inflammatory infiltrates in the pancreas of insulindependent diabetics17,18.

In short, all these studies and many more
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that have followed in the recent past have played a key role in the
establishment

of the

current

thinking

that

IDDM

is

caused

by

complete, autoimmune destruction of the beta cells of the pancreas.
A summary of the main clinical characteristics of the two types
of diabetes is presented

in Table

1. In IDDM,

hyperglycemia

and

ketosis appear suddenly in non-obese children or young adults and
require chronic therapeutic intervention with small doses of insulin.
The typical pathologic findings include insulitis followed by islet cell
destruction. A strong association exists between IDDM and HLA DR3
and DR4.

On the other hand, NIDDM patients tend to present at an

older age with symptoms of more chronic nature, are often obese and
can be treated with dietary restrictions.
insulin-dependent

diabetics

amyloid

In certain fraction of non-

deposits

are

found.

Genetic

predisposition is believed to be strong, however, no association with
HLA types has been observed.

In all populations

NIDDM

is much

more common than IDDM, with the risk of developing NIDDM being
more than 30 times greater19.

2.3.2 Type 1 or Insulin-Dependent Diabetes Mellitus

Following

the

establishment

of

IDDM

as

a

fundamentally

different disease from NIDDM, substantial body of research has been
published on its etiology and pathogenesis.

What is certain about the

etiology of IDDM is that it involves a complex interplay between

a

13

number of genetic and environmental factors.

Genetic factors play

an essential role as evidenced by the involvement of both MHC and
non-MHC predisposition factors.

In Caucasians increased prevalence

of IDDM is seen in individuals with HLA DR3 and DR4 haplotypes.
Furthermore,

individuals who are

DR3/DR4

heterozygotes

have a

twenty to forty fold higher risk than the general population20.

In

contrast, reduced prevalence is found in individuals with HLA DR2
haplotype21.
protection

Other
include

MHC

associated

Tap-1

and

genes

Tap-2

associated

genes

which

with

IDDM

code

for

transporters of antigenic peptides to MHC class I molecules22.

Table 1: Main clinical characterics of the two types of diabetes (from “Insulin ” Aschroft
and Aschroft. (1992) IRL Press.)
Insulin-Dependent-Diabetes
Non-Insulin-Dependent
Type of Diabetes
Mellitus
Diabetes Mellitus
Age of Onset

Juvenile Onsetage
age, 0-30 years
non-obese
short history
severe hyperglycemia
often ketotic

Therapeutic
Requirements

requires insulin therapy
insulin sensitive (small doses of
insulin needed)

Pathology

Type 1 diabetes
islet cell antibodies present
beta cells destroyed by immune
inflammatory cells
low
concordance
among
identical twins
associated with HLA DR3 and
DR4

Genetic Predisposition

Maturity Onset
usually 35 years or more
usually obese
often symptoms for years
moderate hyperglycemia
rarely ketotic unless major
infection
can be treated with diet or
tablets
insulin resistant (large doses
of insulin needed)
Type II diabetes
islet cell antibodies absent
often amyloid in islets
high concordance
identical twins

among
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Apart from the insulin gene, the search for the candidate nonMHC predisposing genes has been rather unfruitful in human IDDM.
The 5’ region of the insulin gene has been shown to be associated
with IDDM, independent
Heterozygosity

of parental transmission and HLA type23.

of the beta chain of the T cell receptor

(TCR)

was

reported in 1987 to have an association with IDDM24, however since
then there has been no convincing evidence that TCR genes influence
susceptibility to disease.
description

Studies of the NOD mouse have led to the

of 10 non-MHC predisposition

major association with MHC loci.

loci,

in addition

to the

These are discussed in more detail

elsewhere in this paper under the subheading of NOD mice.
Many
susceptibility

of

the

studies

described

as a required

but

disease process. As monozygotic
50%

concordance

provide

the

link

of

IDDM,

between

it

the

not

above

sufficient

establish

genetic

component

of the

twin studies have shown only 30is

environmental

diathesis

and

the

influences

that

disease.

The

importance of environmental factors are well established in animal
models of spontaneous diabetes. In NOD mice variation of the diet2"1
or several viral infections26,27 reduce disease susceptibility.
In human populations it is much

more

difficult

to establish

specific direct links between environmental influences and and the
development of IDDM.
this hypothesis.

However, ample evidence exists that supports

Disease frequency varies greatly from country to

15

country

with

countries2".

the

greatest

incidence

found

in

Scandinavian

It seems that in certain colder climates IDDM is found at

a greater frequency.

This is quite interesting,

shown that by raising the

ambient

since

temperature

diabetes can be reduced in the NOD mice24.

the

it has been
incidence

of

Studies of migrants from

countries with low IDDM frequency to countries with high frequency
have shown that they become more susceptible to disease in their
new environment0,31.

Other data from stable populations in Europe

has shown a sudden surge in incidence of IDDM 2.

This change in

Europe represents a two to three-fold increase over a period of 30
years and is clearly evidence
basis

alone.

Some

of the

that cannot be explained
environmental

factors

on genetic

implicated

as

possible triggers of IDDM include viruses, most notably Coxsackie B
virus33 and cytomegalovirus’4, bovine albumin found in cow’s milk'3,
and even stress'6.

The suggested hypothesis is that both Coxsackie B

viral protein and bovine albumin share a sequence with the beta cell
autoantigens,

glutamic

acid

decarboxylase

respectively, and by virtue of molecular mimicry,
directed

against the xenoantigens

cross react

(GAD)

and

p69,

immune reactions
with

the

beta

cell

autoantigens.
The etiologic role of the environmental and genetic influences
seem certain, but the nature and the extent of the contributions that
each makes to the development of disease still requires much work.

.

Once the events that lead up to the break down of self tolerance have
taken place,

the details

of the

effector

autoimmune

cascade

that

follow seem clearer. Even though anti-islet cell antibodies have been
demonstrated both in rodent and human IDDM, there is no evidence
that these autoantibodies are pathogenic since the disease cannnot
be transferred by the serum of the affected mice37. Without a doubt
IDDM is a T-cell dependent

autoimmune disease characterized

by

infiltration and destruction of the pancreatic islets by the cells of the
immune system'8.

Diabetes can be transferred to normal syngeneic

animals by purified T cells from diabetic NOD mice'9.

On the other

hand

by

anti-TCR

monoclonal antibodies which selectively eliminate T cells40.

The two

diabetes

can

be

prevented

in

NOD

mice

subsets of T cells, CD4+ and CD8+, play different roles in this process
(Figure

3).

recruitment

CD4+
and

T
the

cells

play

an

important

activation

of

the

Lymphokines produced by CD4+
Interleukin-3
(TNF-a),

(IL-3),

Tumor

immune

Factor-j3

Tumor

have

extravasation

been
for

shown
various

to

both

effector

(TNF-J3)

Necrosis
and

Macrophage Colony Stimulating Factor (GM-CSF).
TNF-J3

in

the

cells.

T cells include Interleukin-2 (IL-2),

Interferon-y (IFN-y),

Necrosis

role

act

as

mediators

inflammatory

cells41.

Factor-a

Granulocyte-

IFN-y, TNF-a and
of

adhesion
IL-2

and

induced

proliferation of CD8+ T cells42 is one of the most crucial events in the
pathogenesis of IDDM, for it is the army of CD8+ T cells that delivers
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the major "cytotoxic” blow to the JTcell of the pancreas43.
to

T

cells,

macrophages

as

well

have

been

In addition

implicated

in

the

destruction of the beta cells via local cytokine or free radical release.
IL-1, which is released by activated macrophages, has been shown to
have a cytotoxic effect on the pancreatic islets44.
IDDM is clearly an autoimmune disease
evidence

given

above,

which

represents

existing body of scientific knowledge.

as reflected

a minute

astounding

pace

of modern

fraction

of the

Clear understanding of the

etiology and the pathogenesis of IDDM still eludes us.
the

by the

science,

the

However, given

proximity

of

this

presently elusive goal seems certain.

2.4 Calcitonin Gene Related Peptide (CGRP)

CGRP was first described by Rosenfeld and his colleagues in 198345.
The story behind the discovery of this novel neuropeptide
interesting.

Most peptides

come

to our attention

certain biological function that they perform.

is quite

as a result

of

The usual sequence of

events include the purification of the peptide, followed by amino acid
sequencing and lastly the identification of the gene that codes for the
peptide.

In

the

case

of CGRP,

everything

was

reversed

consequence of recombinant DNA technology (Figure 4).

as

a

Figure 4:
The Usual Road Travelled
|Biological|_^ Identification
| Function |

of the Peptide

Ammo Acid

Genomic DNA

Sequence Analysis

Sequence

The Road Less Travelled
Discovery of CORF
mRNA Transcript
Genomic DNA
Sequence

Amino Acid Sequence

Peptide Isolated

Inferred From mRNASequence

and Purified

Numerous Functions Already Shown
New Functions Still Being Discovered

While Rosenfeld and his colleagues were studying the calcitonin gene
transcription, they unexpectedly found a second, structurally distinct
transcript, which they referred to as calcitonin gene related peptide
mRNA.

Through isolation and sequence analysis of the

calcitonin

genomic DNA, and calcitonin and CGRP cDNAs, they discovered that
both CGRP and calcitonin mRNAs were generated by differential RNA
processing from a single genetic locus46 (Figure 5).
cells

the

primary

RNA

transcripts

are

In the thyroid C

processed

to

mRNA

for

calcitonin, while mRNA for CGRP is formed predominantly in neural
tissue47.

Since its discovery, CGRP has become a subject of extensive

research which has revealed the peptide’s important implications as
a chemical messenger of the nervous system.
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Figure 5: Alternative splicing of the Calcitonin gene mRNA transcripts.
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peptide

is co-localized
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C-terminal
peptide
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sensory nerves48 and with acetylcholine
brain, CGRP is broadly distributed

with

detected

predominantly

the

the

blood

atria,

P

stream52’53

around

coronary

in

CGRP is ubiquitous

and

54

in

In the

and especially concentrated

tissues, including the digestive system"1.
in

in

substance

in motorneurons49.

hypothalamic areas and some brainstem nuclei50.

been

CGRP
Precursor

CGRP I 4 aa~|

Proteolytic Processing

Proteolytic Processing

in the peripheral

CGRP
mRNA

3'

Translation

V

CGRP

poly A

i

i
Translation
Calcitonin
Precursor

mti

in

the

vessels

and

It has
heart,
in

the

myocardium"8.
A variety of biological
including

the

modulation

effects have been attributed
of

nicotinic

receptor

neuromuscular junction"6 and of substance

to CGRP,

activities

at

the

P in inflammation"7, a

reduction of gastric acid secretion58, potent peripheral blood vessel
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dilation59'60'61,
cardiac

increased

proliferation

of human

acceleration65,

a regulation

of calcium

endothelial

cells62,

metabolism64

and

insulin secretion66, an increase in body temperature, and a decrease
in food intake66.
demonstrated

Dr. Vignery, and her colleagues, here at Yale, have

that CGRP has potent immunosuppresive

activity

in

vitro by virtue of inhibiting the production of IL-2 by T cells67.
The activation of T lymphocytes leads to the production of IL-2,
a lymphokine which initiates a cascade of cellular events.
cytokines

produced

by immune

cells,

Among the

IL-2 is the earliest

growth

factor produced by T cells upon stimulation by antigen and IL-1.

IL-2

is not only a potent T and B cell mitogen but also a direct activator of
natural killer cells.

Thus, the production of IL-2 is a critical step that

influences the immune response.
By virtue of its capacity to induce the proliferation
differentiation

and the

of multiple T cell subsets as well as the release

of

cytokines, IL-2 plays a key role in the initiation and evolution of the
immune reaction that leads to tissue remodeling
much as the production
defense

mechanisms,

of IL-2 has beneficial

its production

can

or repair.

effects

also be

In as

in immune

associated

with

tissue destruction that accompanies chronic inflammatory reactions
and autoimmune diseases.
regulate immune reactions.

Thus, local control mechanisms may help

Dr.

Vignery

has

demonstrated

that T lymphocytes

express

functional receptors for CGRP which prevents the production of IL-2
by a cAMP-mediated inhibition of IL-2 gene expression67.
From the evidence that has been presented in this section, it
appears that CGRP plays both a regulatory and modulatory role along
the neurovascular, neuroendocrine and neuroimmune axis.

2.5 Non-Obese Diabetic (NOD) Mouse Model
The NOD mouse represents

a model in which

autoimmunity

against beta cells is the primary event in the development of insulindependent

diabetes mellitus (IDDM).

It serves as one of the best

characterized and most widely used models of autoimmune diabetes.
The NOD mouse was derived from a cataract developing substrain of
outbred ICR/JC1 mice by selective breeding at Shianogi Laboratories
in Japan in the early 80’s. Since then many substrains of NOD mice
have been established which differ in diabetes incidence and time of
onset.

Typically 80-100% of female mice and 15-40% of male mice

develop the disease between 3 to 6 months of age.
sex difference

is attributed

increases

the incidence

incidence

in females.

influence

the rate

In these mice the

to the sex hormones,

of diabetes

Environmental

of development

in males
factors,

of the

since

castration

and

decreases

the

such

as diet25,

can

disease.

Furthermore,

animals protected from infections by maintenance in a pathogen free

y,f

,)

cages

have higher

incidence

of diabetes1"*. Crowding

of mice

and

frequent handling also elevates the incidence of diabetes, and this is
believed to be due to stress.
IDDM

is

a

disease

whose

main

clinical

feature

is

hyperglycemia. In NOD mice this is easily determined by whole blood
portable glucose monitor. However, in initial screenings it is more
practical and less expensive to measure glucose levels in urine, since
hyperglycemia

inevitably

leads

to

glycosuria

observed,

then

more

is

glycosuria.

When

acurate

persistent

portable

glucose

monitoring can be initiated.
The pathologic lesion leading to IDDM in both NOD mice and in
humans is the autoimmune destruction of the insulin-producing beta
cells in the pancreas.
followed
pancreas.
the

by

The course of the disease in mice

histological

examination

of

the

surgically

can be
removed

A typical longitudinal histologic examination demonstrates

following69:

at

3-4

weeks

of age,

infiltrating

immune

cells

surround the blood vessels (perivascular infiltration) but the islets are
still clear.
islet

At 6-7 weeks, the infiltrating cells reach the islets (peri-

infiltration).

Between

10-12

weeks,

the

infiltrating

cells

penetrate into the islets (intra-islet infiltration) and the islets become
swollen with lymphocytes.
14-20

weeks,

the

infiltrate

Following the onset of overt diabetes at
disappears,

reduced in size and devoid of beta cells.

leaving

the

islets

greatly
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By staining with antibodies directed
cells,

and

macrophages,

predominate
cells,

it

transfer

prediabetic

been

shown

among the cells first infiltrating,

then by CD8 T cells

adoptive

has

at markers

and B cells69.

of T cells

have

shown

NOD mice did produce

that

of T ceils,

B

macrophages

followed

by CD4 T

Experiments

employing

that

CD4

T cells

from

insulitis following the transfer,

but did not lead to islet destruction or hyperglycemia; the transfer of
CD8 T cells did not produce insulitis or hyperglycemia.
when CD8 T cells were

transferred

However,

together with, or after CD4 T

cells, autoimmune diabetes developed.

Taken together with the data

from the immunohistochemical analysis of the lesions, it seems that
CD4 T cells home to the islets, attach themselves and proliferate, and
enable the later-arriving CD8 T cells to reach the islets and engage in
the destruction of the beta cells70.

Antibodies do not appear to play

any role in the pathogenesis of IDDM in either humans or mice, even
though the presence of several antibodies have been detected before
the onset of overt diabetes7172 73 .
The development of diabetes in NOD mice is under the control
of multiple

genes.

At least ten genes,

both MHC

and non-MHC

related, mappped to nine different chromosomes have been shown to
contribute

to

Susceptibility
chromosome

the
gene

susceptibility
Idd-1

is

of

located

NOD
in

the

mice

to

murine

diabetes.
MHC

on

17, and is a gene complex with two suceptibility loci,
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the class II genes I-AJ3 and
human

DLADQB 1*0302

I-Ea.

I-AJ3 gene

IDDM-associated

instead of aspartate at position 57 4.
other MHC class II product, I-E,
gene.

allele

in

to the

having

serine

NOD mice do not express the

owing to the mutation in the I-Ea

The absence of the I-E product is necessary for NOD diabetes.

The introduction of a normal
completely prevents
was

is homologous

later

presented

I-Ea, as a transgene

diabetes7". However,
by

Podolin

evidence

and Wicker

in NOD mice,

contrary to this

indicating

that

the

expression of I-E in NOD mice is not in itself sufficient to prevent
diabetes6.
The

non-MHC

susceptibility

genes

that play a role

in

NOD

diabetes have been designated Idd-2, Idd-3, Idd-4, Idd-5, Idd-6, Idd7, Idd-8, Idd-9 and Idd-10, and mapped to Chromosomes 9, 3, 11, 1,
6, 7, 14, 4, and 3 respectively.

The nature of each of the non-MHC

susceptibility genes is less well defined in their effect on the disease.
Development of diabetes is mediated through a multifactorial
interaction
genetic loci.

between

Moreover,

interaction between
disease

MHC

incidence

class

and

multiple,

age

and environment.
of

onset

among

The

difference

various

depending on the cleanliness of the housing conditions,
how environmental factors
susceptible genes.

unlinked,

the NOD mouse demonstrates the critical

heredity
and

II genes

can affect

the penetrance

in

colonies,
illustrates

of diabetes-
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Lastly,

one

should

bear

in

mind

that

IDDM

patients

genetically and probably pathogenically heterogeneous.

Thus. NOD

mice might represent only a part of the IDDM population.
animal

model

to

study

human

disease

always

are

Use of an

requires

cautious

interpretation.

2.6 Rat Insulin Promoter and Transgenic Technology

Transgenic technology allows the scientist to incorporate and
express a given gene in a specific tissue or cell type.

In part, this is

possible because of the remarkable ability of selective expression of
specific genes by differentiated eukaryotic cells.

For example,

the

beta cell of the pancreas is the only cell in the body that can express
insulin even though the genetic information for expression of insulin
is present
whether

in all the

insulin

or

cells

any

of the

other

organism.

protein

will

The
be

information

produced

in

of
the

pancreas or in the brain is not contained within the coding sequence
of the insulin gene:
transcriptional

rather it is contained in a number of distinct

control

elements

located

upstream

of the

mRNA

initiation site. These transcriptional control elements collectively are
referred

to as the promoter

techniques

a given gene

region.

could be

Through

attached

to

recombinant
another

DNA

promoter
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region which would result in the expression of the given gene only in
the cells where the promoter has a permit of a sort to act in.
In the transgenic mouse that we created,

the CGRP gene was

linked to the rat insulin promoter, which would insure the targeted
expression of CGRP to the beta cells of the pancreas. Along with the
development of the transgenic technology in mid 80’s, the rat insulin
promoter,

which

was

first

described

in

1979

by

Lomedico

and

colleagues77, has been used to express several cytokines in the beta
cells.
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3 MATERIALS AND METHODS
3.1 Reagents
Human CGRP, CGRP8-37, mouse amylin and human CGRP RIA were
purchased from Peninsula Laboratories (Belmont).

Complete Freund

adjuvent and M-MLV reverse transcriptase were purchased from
Gibco-BRJL (Grand Island).

Keyhole Lympet Hemocyanin (KLH) was

purchased from Calbiochem (La Jolla).

Unless otherwise stated, all

reagents were obtained from Sigma (St Louis)

3.2 Antibodies
The following Abs were used: guinea pig anti- human insulin
(BioGenex, San Ramon), mouse anti-porcine glucagon (Sigma, St
Louis), rabbit anti-human CGRP (Penninsula, Belmont), biotinylated
rat mAb anti-mouse Ly5 (B220) (Caltag, South San Francisco, CA),
biotinylated rat mAbs anti-mouse CD4, CD8a and CD4+red613
(1/500) (GibcoBRL, Grand Island), biotinylated anti-mouse CD8+
(TIB 105, ATCC), anti-mouse CD4+red613 (1/500) (GibcoBRL, Grand
Island, NY), anti-mouse B220+ and avidin-phycoerythrin
(PharMingen, San Diego), anti-mouse-TCR+-FITC (H57-557, ATCC),
donkey anti-guinea pig-FITC and -CyS^M

donkey anti-mouse-FITC

and -CyS^M, goat anti-rabbit-CyS^M (Jackson ImmunoResearch Lab,
Inc., West Grove), streptavidin-phycoerythrin (Calbiochem, La Jolla,
CA), goat anti- mouse Ig (H+L) coupled to magnetic beads (Biomags,

8-4340G, Cambridge), hamster mAb anti-mouse CD3e (2C11-145.
ATCC).

3.3 Cells
Cytotoxic T-Cell Line (CTLL) and T cell lymphoma EL-4 were obtained
from ATCC (Bethesda).

3.4 Construction Of The pRIP-hCGRP-Ex2 Transgene

The human CGRP gene cloned into pGEM4 plasmid vector (Promega)
was kindly provided by Dr. Gilbert Cote from MD Anderson Cancer
Center in Houston, Texas.

This construct was named pGEM4-CGRP.

The TGCA splice site upstream of Exon 4 was deleted. The resulting
gene preferentially leads to the production of CGRP mRNA as shown
in Figure 5.
promoter

pBS-SK-RlP plasmid vector containing the rat insulin

was

kindly

provided

by

Dr.

Dominique

Piearella

from

Howard Hughes Institute at Yale University School of Medicine. CGRP
gene was excised

out of pGEM4-CGRP

using Hind

III restriction

enzyme, agarose gel purified, and ligated into the Hind III site of pBSSK-RIP (Figure 6).
competent
(Settings:
2.5 V).

The ligated

DNA was transformed

cells by electroporation
Capacitance 25 microFad.

using Bio

Rad

into

DH5-a

Electroporator

Resistance 200 ohms, Voltage

Electroporated cells were grown in 1ml SOC

(LB broth rich

in glucose) medium for 1 hour at 37°C, and 150ul was plated onto

■
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Ampicillin/agar plates and incubated overnight at 37°C.
were

picked

medium.

and

cultured

overnight

at

37°C

in

48 colonies
LB+Ampicillin

DNA plasmid miniprep was performed on all 48 cultures

using the “boiling method” described by Maniatis78. 10 ul from each
DNA plasmid miniprep was digested with Hind III to determine which
sample

contained

the

CGRP

gene

insert.

To

ensure

the

correct

orientation of the inserted CGRP gene, plasmids containing the CGRP
insert were subjected to further digests by Nhe I. Xmn I, Ail il, Apa I,
Kpn I, and Spe 1.
hCGRP

(Figure 6).

We had therefore

constructed

the pBS-SK-RIP-

As discussed in the background section on CGRP

the exon 1 of the Calcitonin gene is non-coding and only serves as a
regulatory element which could interfere with the insulin promoter
driven targeted expression of CGRP in the beta cells of the pancreas.
Thus, the sequences upstream of BstB I site, which included Exon 1
and Intron 1, were removed from the construct as follows.
RIP-hCGRP was double digested with BstBI and EcoR I.
was

run

on

a

1%

agarose

gel,

and

the

larger

pBS-SKThe digest

fragment,

which

contained the pBS-SK, RIP and Human CGRP from exon 2 onward,
was purified by electroelution as described in Maniatis78. The ends of
the purified fragment were ligated using a 27 base-polylinker (EcoRIEcoRV-Xbal-BstBI, obtained from oligonucleotide
at Boyer

Molecular

Biology Center).

Following

synthesis services
ligation,

DNA was

transformed into DH-5a competent cells by electroporation, grown
overnight
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Figure 6: A: pBluescript SK (pBSSK) plasmid. B: pBS-SK-RIP
constructed by inserting rat insulin
promoter (RIP) into pBS-SK
between BamH I and EcoR I sites.
C: pBS-SK-RIP-hCGRP
constructed by inserting CGRPgene
into pBS-SK-RIP at Hind III site.
D: pRIP-hCGRP-Ex2 constructed
by excising Exon 1 and Intron
I with EcoR I and BstB I restriction
endonucleases and ligating the
ends of the larger fragment with
EcoR I - EcoR V - Xba I - BstB I
poly l inker.
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cultures, and mlnipreped

as described

named pRIP-hCGRP-Ex2 (Fig. 6).
construct,

it was subjected

above.

This construct

To insure the integrity

to partial restriction

was

of the new

map analysis using

EcoR I, Hind III, Xba I. BstB I, Xmn I and BssH I.
pRJP-hCGRP-Ex2 was “maxipreped”
column twice as described

in Maniatis78.

and precipitated

in CsCl

Ethidium bromide

from

purified DNA was extracted using water saturated Butanol. Plasmid
DNA was precipitated

with

EtOH

and resuspended

in TE

lOOul of the plasmid DNA was digested with Not I and
isolate the RIP-hCGRP-Ex2

buffer.

Hind III to

sequence from the pBS-SK vector. The

separation was performed on 1% agarose gel and the RIP-hCGRP-Ex2
fragment isolated by dialysis.

The isolated

fragment

purified using Elutip-d DNA column (CalBiochem).

was further

To desalt the DNA

samples prior to injection into mouse embryos, they were
with Millipore 0.05 micron round filter paper.

dialysed

DNA was quantified

and diluted to the concentration of 5 ng/ml in sterile double distilled
water.
2 picol

of this

5ng/ul

RIP-hCGRP-Ex2

were

injected

into

fertilized eggs from NOD mice, and implanted in the uterine horns of
pseudopregnant

BALB/c

female mice using standard procedures79.
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3.5

Screening

of

RIP-hCGRP-Ex2

Transgenic

Mice

and

Establishment of Colonies
3.5.1 Genomic DMA Preparation:
Solutions:

1. Tail buffer - 50 mM Tris pH 8.0, 100 mM EDTA,
lOOmM NaCl, 1% SDS
2.

Saturated

(ratio

phenol/chlorophorm/isoamyl

alcohol

25:24:1)
3. Chlorophorm/isoamyl alcohol (ratio 24:1)
Approximately a 5 mm portion of the tails from 2 week old

mice were excised.

700 ul of tail buffer and 25 ul of Proteinase K

(lOmg/ml) were added to each of the tails in an 1.5 ml eppendorf
tube and

incubated overnight at 55°C.

phenol/chlorophorm extractions,
extraction.

DNA was isolated by two

followed by a single chlorophorm

600 ul of ice cold EtOH was added to the aqueous phase

which was then precipitated in a microcentrifuge at 14,000 rpm for
30 minutes.

The supernatant was discarded, the pellet washed with

70% EtOH and suspended in 100 ul of H20.
determined

using a spectrophotometer.

DNA concentration was

A reading

of 1.0 optical

density (O.D.) at 260 nanometer wavelenght represents to 50 ug/ml
of double stranded DNA.
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3.5.2 Tail DMA Analysis by Southern Hybridization:

Solutions:

Recipes for all of the following solutions described
Maniatis78.

in

1. 20 x SSC
2. Denhardt’s Solution
3. Hybridization buffer - 6 x SSC, 0.5% SDS, 0.01M
EDTA, 5x Denhardt’s Solution, 100 ug/ml
denatured Salmon Sperm DNA.
4. Denaturing Solution
5. Neutralizing Solution
10 ug of each tail DNA sample was digested with Pvu II and run
on a 1% agarose gel. The gel was then bathed in 0.25 M Hydrochloric
acid

solution for 20 minutes.

solution for two

20 minute

It was then placed

intervals,

intervals in neutralizing solution.
nitrocellulose

membrane.

denaturing

by two

20 minute

DNA was then transferred

Following

crosslinked to the membrane

followed

in

the

transfer,

by ultraviolet crosslinker.

DNA

to a
was

This filter

was prehybridized in hybridization buffer for 2 hours at 65°C.

A RIP-

CGRP probe, generated by excising a 647 bp fragment from the RIPCGRP-EX2

plasmid

using

Xbal,

was

used

to

identify

transgene

positive mice. This probe was denatured by boiling for 5 minutes at
95°C, was then added

to the

hybridization

overnight at 65°C in a shaking water-bath.

buffer

and

incubated

The filter was washed

•
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successively with 3 x SSC + 0.1% SDS at 65°C two times, followed by
0.3 x SSC + 0.1% SDS twice, and eventually 0.1 x SSC + 0.1% SDS at
65°C. After the final wash was performed

the filter was wrapped in

SaranWrap and exposed onto a film with an intensifying screen at -70
C for 36 to 48 hours.

3.6 Immunohistology
Tissue immunostaining was undertaken for twro reasons: (1) to
ensure

that CGRP was being

produced

in

the

beta

cells

of the

pancreas and (2) to check whether CGRP was aberrantly expressed
in any other peripheral organ.
Pancreata were collected from F0 NOD-CGRP and NOD mice, fixed at
4 °C overnight in periodate / lysine / paraformaldehyde fixative (Ref
PNAS 18), processed sequentially through graded

sucrose solutions

[10%, 20%, and 30% (wt / vol)], and snap-frozen in tissue-Tek OCT
(One-Touch,
(EM

Science,

collected
Scientific,

Miles (West Haven) by submersion in 2-methylbutane
Gibbstown).

onto

8-10

gelatin-coated

mm

thick

slides

serial

sections

(Superfrost/Plus,

were
Fisher

Pittsburg) and blocked with a solution containing 0.6 %

Triton X-100

/ 33% normal

goat serum

/ 0.9 M NaCl /

phosphate buffer, pH 7.4 for at least 2 hr at rt.

0.2

M

The sections were

then washed 3 times with a solution containing 0.3% Triton X-100 /
4 M NaCl / 0.2 M phosphate buffer prior to being incubated with
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rabbit anti-human CGRP (1/2000) for 2.5 hr at rt.

This polyclonal

antiserum was pre-incubated with 20 mg / ml of mouse amylin to
eliminate its cross-reactivity with amylin.

The sections were washed

3 times as described above and incubated for 1.5 hr at rt with goat
anti-rabbit-CY3™ (1:100).
For the histoimmunochemical analysis of pancreatic islets from the
NOD and NOD-CGRP colonies, half pancreata were fixed for 24 hr in
10%

phosphate-buffered

formalin,

paraffin-embedded,

sectioned and stained with hematoxylin and eosin.
mononuclear

infiltrates,

in

and

around

Langerhans, along with the percentage
were

recorded

other half pancreata were
described

above.

The

processed

primary

The presence of

capillaries

and

of islets with

on twenty sections selected

serially

islets

peri-insulitis

every 5 sections.

used

were

anti-human CGRP (1/2000),

biotinylated

(B220)

or CD8a

CD4

(1/20),

secondary

(1/20).

antibody

The

sections

as follows:

anti-rabbit-Cy3TM (i/lOO),

or

and

1/200

were

1.5 hr at rt
donkey

guinea pig-FITC or -Cy3^M (1/100 and 1/200 respectively),
anti-mouse-FITC or -Cy3TM (1/100

rabbit

rat mAbs anti-mouse Ly5

washed 3 times as described above and incubated for
with the appropriate

as

as follows:

guinea pig anti-insulin (1/50), mouse anti-glucagon (1/200),

(1/20),

The

for immunocytochemistry

antibodies

of

donkey

respectively),

streptavidin-phycoerythrin

anti¬

goat

(1/200).

The surface area of the lymphocyte infiltrate around each islet was
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estimated

morphologically

nuclei bv fluorescein.
lymphocytes,

using the

non-specific

labeling

of

the

The percentages of CD4, CDS and Ly5 (B220)

labeled with phycoerythrin

conjugate, was estimated

and expressed as percent of total immune infiltrate.

3.7 Islet Isolation and Culturing
Solutions:

1.

Hanks Balanced

Salt Solution

(HBSS)

- For

every 100 ml of HBSS use 1 ml penicillin-streptomycin (Gibco), 3.25
ml Hepes (Gibco), 2 ml of 7.5% Bovine Serum Albumin (Gibco).

1 mg

DNAse (Boehringer Mannheim)
Islets were

isolated

from

mice. To digest the pancreatic
HBSS for 5 minutes on ice.
0.075%

of

collagenase

additional minutes.

in

the

pancreata

of freshly

tissue, it was treated

sacrificed

with 5 ml of

Supernatant was removed and 5 ml of
HBSS

was

added

and

shaken

for

5

Above steps were repeated for two more times.

After the third shake 5 ml of Bruff s + 5% Fetal Calf Serum was added
to to each vial and incubated for 5 minutes at room temperature.
This was a washing step and was repeated two more times. Following
the final wash the vials were left in the washing solution and placed
on ice until the the next step when islets were picked.
microscope the islets were identified

Under the

as suspended white spheres,

picked with a narrow tipped glass pipets, and placed in a clean petri

'

■
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dish. The

islets were

cultured

in Bruffs +

5% Fetal

Calf Serum

media.

3.8 Bioactivity and Proliferation Assay for CGRP
The murine T cell line EL-4 produces IL-2 in response to activation
with

PMA (ATCC).

This line

does not produce

CGRP and CGRP

inhibits its production of IL-2 in response to Phorbol
13-Acetate

(PMA).

behind the bioassay.
presence of PMA

Figure

7

graphically

illustrates

12-Myristate
the

principle

EL-4 T cells are cultured for 24 hours in the
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Figure 7: EL4/1L2 Bioassay Principle. A: Phorbol 12-Myristate 13-Acetate (PMA)
stimulates EL-4 T cells to produce 1L-2 which in turn stimulates CTLE cells to
proliferate. B: CGRP decreases IL-2 production bx EL-4 T cells. Decreased IL-2
production ranslates into decreased CELL proliferation.

(5ng/ml) and log2 dilutions of supernatant to be assayed for CGRP
activity.

Positive

controls

include

medium

increasing concentrations of rat CGRP.
cells

are

added

to

CTLL,

a

proliferation depends on IL-2.
the amount of [^H]

mouse

supplemented

with

Supernatants from EL-4 T

cytotoxic

T

cell

line

whose

Extent of proliferation is measured by

Thymidine

incorporation

by

CTLL.

A dose-

dependent response analysis of CTLL cells to recombinant human IL2 is performed in each assay to define the IL-2 standard curve and to
determine the concentration of IL-2 produced by EL-4 T cells and
therefore estimate the potency of CGRP.
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3.9 Breeding of Mice

Mice were bred

and kept in sterile

filtered

cages.

For breeding

purposes a positive transgenic male mouse was always placed in the
same cage with two negative transgenic females

and if successful

impregnation

weeks,

was

not

observed

within

three

transgenic negative females were placed in the cage.

different

When breeding

a transgenic positive female mice, they were

always placed with a

single

and

transgenic

negative

male

mouse,

once

again

if

impregnation did not occur in 3 weeks, the transgenic negative male
mouse was replaced.

The newborn progeny were screened for the

presence of the R1P-CGRP transgene at the age of 2-3 weeks by tail
DNA analysis.

3.10 Diabetes Monitoring
Animals

were

monitored

for

glycosuria

Chemstrip UG (Boehringer Mannheim).

every

week

using

If animals were positive in

two consecutive urine tests, blood glucose was measured using One
Touch

blood glucose meter (Lifescan, Inc.).

Mice were considered

diabetic when their blood glucose levels reached 250 mg/dl.
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3.11 Statistical Analysis
Results were analyzed using either the Student t test or the test
for

significance

appropriate.
power

of

difference

between

two

proportions,

when

To determine the number of animals needed to reach a

of 80% and an a level

of 0.05

using

a two

performed a power analysis as described elsewhere"0.

tail

test,

we
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4 RESULTS
4.1 pRIP-hCGRP-Ex2 Construct
As explained in materials and methods following the excision exon 1
and intron 1 from pBS-SK-RIP-hCGRP,
(Figure

2).

Both

these

constructs

mapping by various endonucleases.

pRIP-hCGRP-Ex2 was derived

were
The

subjected

to

restriction

results of these digests are

presented in Figure 8 and they show great agreement between the
expected and the observed fragment sizes.
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Figure 8: A: To ensure the proper engineering of the pRIP-hCGRP-Ex2 transgene, the
pBS-SK-RIP-hCGRP and pRIP-hCGRP-Ex2 constructs were subjected to restriction
mapping as shown below. B: Fragments originating from pBS-SK-RIP-hCGRP and pRIPhCGRP-Ex2 are bold when differing in size.

Lane #
l
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

DNA Sample
lkb Ladder
Uncut pBS-SK-RIPhCGRP
Uncut pRIP-hCGRPEx2
pBS-SK-RIP-hCGRP
pR!P-hCGRP-Ex2
pBS-SK-RIP-hCGRP
pRIP-hCGRP-Ex2
pBS-SK-RIP-hCGRP
pRIP-hCGRP-Ex2
pBS-SK-RIP-hCGRP
pRIP-hCGRP-Ex2
pBS-SK-RIP-hCGRP
pRIP-hCGRP-Ex2
pBS-SK-RIP-hCGRP
pRIP-hCGRP-Ex2
lkb Ladder

Restriction
Enzymes

Expected
fragments (kb)
12
9.5

EcoRl & Hind III
EcoRI & Hind III
Xbal & Hind III
Xbal & Hind III
BstBI & Hind III
BstBI & Hind III
XmnI
XmnI
EcoRl & Spel
EcoRI & Spel
EcoRl & BssHI
EcoRl & BssHI

3.5. 8.5
3.55, 5.95
0.6, 2.95, 8.5
0.6, 2.95, 5.95
2.5, 3.55. 5.95
no 2.5, 3.55, 5.95
2.1, 2.3, 7.6
2.1, 2.3, 5.1
0.6, 3.5, 3.7, 4.2
0.6, 1.7, 3.5, 3.7
3.7. 8.3
1.2, 8.3

44

4,2 Beta cells from NOD-CGRP transgenic mice express CGRP
Three NOD-CGRP transgene positive founders were

identified

by Southern blot analysis of tail DNA (lines 42, 44. 46).
expression

of

the

immunoeytochemistry
reaction (RT-PCR).

transgene

and reverse

was

transcriptase

Specific

determined

by

polymerase

chain

Among the three transgene positive lines, two (44

and 46) expressed immunoreactive-CGRP in the pancreas, with mice
from line 44 showing the strongest signal.
selected

for breeding

CGRP mice
localized

were

with

and analysis.

co-stained

that

of CGRP

produced by beta cells.
lung, kidney,

with
(Fig.

Progeny from line 44 were

When islets from these NODanti-insulin Abs,
9)

indicating

the

that

signal

co¬

CGRP

was

None of the other tissues examined (brain,

thymus, spleen,

intestine,

liver,

bone

marrow)

from

both NOD-CGRP and NOD littermates expressed detectable level of
immunoreactive CGRP.

Of note, immunoreactive-CGRP was detected

in nerve endings present in most tissues examined,

including

pancreas of both NOD-CGRP and NOD littermates.

To investigate

whether the CGRP transgene was expressed

the

in other tissues, RNA

was extracted from organs and isolated islets, and subjected to RTPCR analysis.

As expected

PCR

products

were

detected

pancreas of transgene positive mice as well as in the

in

kidney

10A), a frequent site of expression of the rat insulin promoter81’82.

the
(Fig
No

expression of RIP-CGRP was seen intissues other than pancreas and
kidney even though we performed
with Southern analysis.

35 cycles of PCR and followed it

Cultured islets from NOD-CGRP mice, but

45

not from

NOD littermates,

expressed

time points examined (Fig. 10B).

RIP-CGRP

transcripts

at all

46

Figure 9: CGRP co-localizes with insulin in islet cells from NOD-CGRP mice.
Frozen sections from pancreata of NOD-CGRP mice stained with anti-insulin
antibodies (A) and anti-human CGRP (B) reveal the co-localization of insulin and
CGRP. Beta cells from NOD mice react with anti-insulin but not with anti-CGRP
Ab (D).

47

Figure 10: Human CGRP is transcribed from die RIP-CGRP transgene. RNA
extracted from pancreas, kidney, spleen, liver, lungs, thymus, brain and
Langerhans islets of NOD-CGRP and NOD mice was analyzed by RT-PCR and
the PCR products subjected to Southern blot hybridization using the RIP-CGRP
probe. The predicted 440 bp RT-PCR product from RIP-CGRP mRNA was
detected in the pancreas, in the kidney (A) and in the islets cultured for 24, 48 and
72 hours {B) of NOD-CGRP transgenic mice.
No signal was detected in
transgene negative attenuates.
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4.3 Beta cells from NOD-CGRP mice produce bioactive CGRP
To investigate

whether

the

transcripts

encoded

by the

RIP-

CGRP transgene were expressed by the beta cells as a biologically
active

peptide,

supernatants

mice and transgene
immunosuppressive

negative

from

isolated

littermates

activity.

Islet

islets

were

from

NOD-CGRP

assayed for CGRP-

supernatants

from

NOD-CGRP

mice inhibited the production of IL-2 by EL-4 cells (Fig.

11).

The

potency of

Figure 11: Production of biologically active CGRP by islets from transgene positive
(A, M ) and transgene-negative littermates (B, 0 ). One hundred islets per well were
cultured in 0.5 ml of culture medium for one to five days. Immunosuppressive activity
of the supernatant was assayed using the IL-2-producing mouse T cell lymphoma EL4. In parallel EL4.IL-2 cells were cultured in either medium alone ( O and O) or
supplemented with supernatant derived from islets and previously incubated with the
antagonist CGRP 8-37 (O and O).

IL-2 concentration in the supernatants was

determined by fi'H] thymidine incorporation of CELL cells.

g_

CGRP positive

-H-

CGRP positive

0.1

-•-

CGRP negative

»

CGRP negative

1

10

[EL4 supernatant], percent

.
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CGRP in these islet supernatants was comparable
with

10"® M human CGRP (data not shown).

cells with

10"5

Preincubating

supernatants

suggesting

the inhibitory effect of the

that

the

effect

mediated by CGRP produced by the transgenic islets.
detected
littermates.

in

EL-4

M of the truncated form of CGRP (CGRP8-37) which

acts as a CGRP antagonist67 prevented
transgenic

to that obtained

the

islet

supernatants

This indicated

that beta

from
cells

was

No activity was

transgene

from

indeed

negative

NOD-CGRP

mice

produced active CGRP.

4.4 Production of CGRP by beta ceils prevents diabetes in male and
reduces the incidence in female NOD transgenic mice
The incidence of diabetes in our NOD colony reached 71% in
females after 46 weeks of age and 40 % in males after 63 weeks and
was therefore similar to that reported by other authors83’84 (Fig. 12).
While none of the male NOD-CGRP mice
26% of the female did.

developed

diabetes,

The incidence of diabetes was thus reduced

by 63% in females aged 52 weeks

and older

(p<0.05) when using a two tail test78 (Fig.

12).

and was significant
Using the test for

significance of difference between two proportions, the z

value was

superior to 4 in all groups indicating that the two proportions were
significantly different at a 0.001 level.
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Figure 12: Incidence of diabetes in NOD-CGRP transgenic mice. Glucosemia was
monitored even• other week using One-Toucli Basic Meter. A reading of 250 mg/dl
or more indicated the onset of diabetes.

Age in weeks

4.5 NOD-CGRP transgenic mice are immunocompetent
To
lymphoid

ensure

that

development

experiments.

First,

CGRP

did

not

and function,
we

have
we

determined

a

systemic

performed
whether

development was altered in NOD-CGRP mice.

T

effect

the
and

on

following
B

cell

As indicated in fig 13A

and Table 2, lymphocyte profiles in thymus, spleen and lymph nodes
from NOD-CGRP transgenic mice were indistinguishable from those
of negative littermates suggesting that CGRP production by beta cells
altered

neither

composition of

T

and

B

cell

development

nor

the

cellular
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Table 2. FACS analysis (in %) ofCD4+, CD8+, CD4+CD8+ and Ly5 B220
lymphocytes in lymph nodes, spleens and thymus of 2 NOD control mice and 2 NODRIP-CGRP transgenic mice._

CD4+

CD8+

NOD

NOD-CGRP

Lymph nodes

44/55

52/49

Spleen

34/31

27/31

Thymus

13/13

13/ 14

Lymph nodes

18/21

20/19

Spleen

14/13

12/ 12

5/4

4/4

Lymph nodes

0.5 / 0.5

0.6 / 0.6

Spleen

0.3 / 0.3

0.5 / 0.3

Thymus

78/80

78/79

Lymph nodes

36/22

26/29

Spleen

45/40

54/51

nd

nd

Thymus
CD4+CD8+

B220

Thymus

lymphoid

tissues.

In

addition,

T

cells

responded

normally

to

polyclonal activator such as anti-CD3 and to allogeneic stimulation in
vitro, further suggesting that T cell differentiation was not affected by
the local production of CGRP (Fig. 13B).

We then analyzed whether

CGRP could interfere systemically with the priming of naive T cells in
lymphoid

organs

analyzed

the

that

do

not

express

antigen-specific

T

cell

immunization in vivo with this antigen.

the

transgene.

response

to

Thus,
KLH

we

after

As shown in figure 13C, NOD-

CGRP mice responded to KLH immunization and the response was
similar to that of transgene negative littermates.

Thus, in NOD-CGRP

mice,

normally

lymphoid

cells

appeared

to

develop

and

mice

remained immunocompetent.

These data indicated that CGRP had

no apparent systemic effect, an observation which was corroborated
by the low serum concentration of immunoreactive

CGRP in NOD-

CGRP mice, similar to that of transgene negative littermates (males:
0.49 vs 0.41 ng / ml, females:

0.60 vs 0.62 ng / ml, respectively).
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Figure 13:

Expression of CGRP by pancreatic beta cells of the NOD-CGRP mice has no

detectable systemic effect on the immune response. A: FACS profile of CD4+CD8+’ CD4 +
and CD8+ T lymphocytes, and 8220 B lymphocytes from spleen, lymph nodes and thymus of
NOD-CGRP and NOD littennates.
B: anti-CD3 activation, allogenic and isogenic
stimulation; allogenic stimulation was performed using as APCs spleen cel's from CBA/CA
(H2k) mice. C: NOD-CGRP and NOD mouse lymphocyte response to KLH immunization. T
cell-enriched lymph node cells from NOD (circles) and NOD-CGRP mice (squares) were
cultured at increasing density (1,2 and 4 x 1 (P cells / well, black, grey and white symbols
respectively) in Bruff medium supplemented with KLH (0.16 to 100 pg / ml).

(squares, NOD-

CGRP mice; circles, NOD mice; triangles represent spleen cells from NOD mice (H28,7).

CD4+

CD4+

A

(3H) Thymidine incorporation (log, cpm)

ctCD3

Allogenic

-- *- -

391 M -. 15w

- —„

392 M -, 15w

Lymph node, cell number

B

C
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4.6 The production of CGRP by beta ceils partially prevents periinsultitis in NOD-CGRP males
To investigate whether lymphoid cells infiltrated the pancreas
of NOD-CGRP males which do not develop diabetes,

their pancreata

were analyzed histologically at different ages and compared to those
from NOD littermates (Table 3).

However, due to the late onset of

diabetes (30 week) in NOD male, most animals were maintained alive
expecting a possible delayed onset of the disease in NOD-CGRP mice.
Thus, a limited number of animals were sacrificed for histochemical
analysis of the pancreatas.

Table 3. Incidence of peri-insulitis in NOD-CGRP and NOD male mice.

Age, (weeks)

Mice

developping

peri-insulitis,

(%)

Islets

with

peri-insulitis

(%)

NOD (n)

NOD-CGRP (n)

NOD (n)

NOD-CGRP (n)

13

100 (3)

25 (4)

25 (406)

25 (89)

18-20

100 (4)

33 (6)

68 (271)

25 (336)

While all male NOD mice had developed

peri-insulitis by the

age of 13 weeks, only 25% of NOD-CGRP male mice did so.

At that

age, only 25% of the islets presented peri-insulitis in both groups.

By

the age of 18-20 weeks, the percentage of transgene positive males
with peri-insulitis increased to 33% while their percentage of islets
presenting peri-insulitis remained constant (vs 68% in NOD male).
Although the low number of mice

observed in each group did not
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allow statistical analysis, CGRP expression by beta cells appeared to
reduce the incidence of peri-insulitis.

4.7 The infiltrating leukocyte population is similar in NOD-CGRP
and NOD littermates
To characterize the pancreatic infiltrate from male NOD-CGRP
and

NOD

mice,

pancreata

containing

insulin-positive

cells

were

subjected to immunocytochemical analysis using anti-CD4, -CD8 and
-B220 Abs.
transgenic

The lymphocyte
negative

mice

population
during

surrounding

the

peri-insulitis

the

islets of

stage

was

composed of a majority of B220+ lymphocytes that represented more
than 60% of the total infiltrate.

CD4+ cells represented 30 % while

CD8+ cells represented up to 40 % of the total infiltrate.

Similar

ratios

positive

were

observed

in

the

infiltrates

from

transgenic

littermates in which the percentage of CD4+ and CD8+ cells reached
10-20 % and 5-10 %, respectively.
cells surrounding the islets

Comparable

of NOD mice

ratios of T and B

have been

reported*"’’86.

These data indicated that the local production of CGRP did not affect
the composition of the immune infiltrate

present

during

the

diabetic stage with regard to B and CD4/CD8 T lymphocytes.

pre¬

■
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5 Discussion
The present study demonstrates that the targeted production of
the immunosuppressive neuropeptide CGRP to beta cells is sufficient
to prevent the onset of diabetes in male and to decrease its incidence
in female NOD mice.

This prevention is most likely due to a local

immunosuppressive effect of CGRP as it is not associated with
generalized

immune suppression.

Indeed,

the average

lifespan

transgenic animals was longer than nontransgenic littermates,
comparable

normal

mouse

strains,

suggesting

that

the

a
of

and

localized

expression of CGRP was not acompanied by undesirable side effects.
Although the mechanism by which this immune suppression occurs
locally has not been definitively elucidated,

islets isolated from our

transgenic mice produce active CGRP with a potency estimated
10"8

M

CGRP,

production

a

concentration

by Thl

cells

that

in vitro67.

prevents

IL-2

This suggests

and

that

to

IFN-y

the

local

concentration of CGRP released by beta cells in vivo may be sufficient
to alter the onset of diabetes.
Thl cells have been shown to accelerate diabetes in NOD mice*7
and are most likely targeted by CGRP in our transgenic mice.

CGRP

may therefore inhibit the induction or expansion of autoreactive Th 1
cells

either

directly

as

we

reported

earlier67

or

indirectly

by

inhibiting antigen presentation by local antigen presenting cells such
as dendritic cells as described in other models*8.

Thl cytokines are
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also thought to be responsible for the activation of other effector cells
which can destroy beta cells.

In fact CD8+ T cells,

NK cells and

mediators released by activated macrophages have been implicated
in the destruction of beta cells*9.

We can therefore

postulate that

CGRP might locally restore an immune balance by either repressing
the production of deleterious Thl cytokines (IL-2. IFN-y and TNF-a)
and/or

favoring

production

of

cytokines such as IL-4 which has been shown to be protective

for

diabetes"0.

a

Th2

response

Furthermore,

leading

to

the

we cannot rule out that CGRP may act

directly on other effector cells such as NK91 or macrophages92.
Vignery

previously

has

demonstrated

that

macrophages

Dr.

express

functional receptors for CGRP4' and more recently that CGRP down
regulates the production of TNF-a (Millet and Vignery. unpublished
data).

Additional characterization of the cells infiltrating the islets

and determination of their cytokines produced in NOD-CGRP mice
are required to address these issues.
Importantly,

although NOD-CGRP

males

do not develop

the

disease, they still exhibit a perivascular and peri-islet accumulation
of lymphoid
lymphoid

cells.

While

the

proportion

cells appears lowered,

does not appear modified

of islets surrounded

the composition of the

by the expression

confirmed by further investigations,

by

infiltrates

of the transgene.

If

this would suggest that CGRP
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might protect from diabetes by preventing the infiltration and clonal
expansion of immune cells around the islets.
Thus the local expression of the immunosuppressive

peptide

CGRP by beta cells prevents their destruction and therefore diabetes
in NOD mice.

This observation opens possibilities to treat or prevent

diabetes by engrafting islets expressing CGRP into NOD mice.
From the concept that Thl cells contribute to the pathogenesis
of several

organ-specific

autoimmune

diseases,

targeted

immune

intervention aiming to restore an immune imbalance based on a cellspecific

transgene

expression

of

appears as a promising approach.
be

applied

to other

an

immunosuppressive

peptide

Similar targeted gene therapy can

organ-specific

autoimmune

diseases

such

as

collagen-induced arthritis, Hashimoto's thyroiditis, Grave's disease or
to conditions in which immune cells are beleived to be pathogenic
mediators.
Finally, an alternative and somewhat unlikely possibility

which

has not been disproven by our studies is that the transgene effect
seen can be the result of the transgene having randomly inserted
into, and thus disrupting the function of, a diabetes
gene.

Since

such

inactivating one allele

susceptibility
would

make

genes

are

the animal

susceptibility

mainly

recessive,

diabetes

resistant.

However improbable this and perhaps other explanations may seem,
inherently uncertain nature of science forces us to humbly accept
the fact that if

59

some event is improbable, that does not necessarily mean that it is
impossible.

BIBLIOGRAPHY
1 O'Gradv RT (19X4): Evolutionary theory and teleology. Journal of Theoretical Biology.
107 (4):563-78.
2 Klein J (1982): “Immunology: The Science of Self-Nonself Discrimination.” New York:
John Wiley.
3 Burnet, M.F. (1959): ‘The Clonal Selection Theory of Acquired Immunity.” Cambridge
University Press.
4 Kappler, J.W., Roehm. N., Marrack, P.( 1987): T cell tolerance by clonal deletion in the
thymus. Cell (49):273-28Q.
5 Burnet, M.F. (1969): “Self and Non-Self.” Cambndge University Press.
6 Cohen, I.R., Young D.B. (1991): Autoimmunity, microbial immunity and the
immunological homnculus. Immunology Today (12): 105-110.
7 Avrameas, S (1991): Natural autoantibodies: From “honor autotexicus” to “gnothi
seaton.” Immunology Today (12): 154-159.
8 Katz, J.D.. Wang, B., Haskins, K., Benoist, C., Mathis, D. (1993): Following s
diabetogenic T cell from genesis through pathogenesis. Cell (74): 1089-1100.
4 Jerne N.K. (1974): Towards the network theory of the immune system. Ann Immunol
Inst Pasteur (125):373-389.
10 Barnett, A.H. (1987): Immunogenetics of Insulin Dependent Diabetes. MTP Press
Limited.
11 Babbit, B.P., Allen, P.M., Matsueda,G., Haber, E., Unanue, E.R. (1985): Binding of
immunogenic peptides to la histocompatibility molecules. Nature (317):359-361.
12 Bomstein, Lawrence (1951): Two types of diabetes mellitus, with and without available
plasma insulin. British Medical Joumar (1)....
13 Porter, A.M. (1972): Diabetes in identical twins. Lancet 2(789): 1250-1251.
14 Nerup, J., Platz, P., Andersen O.O., Christy, M., Lyngsoe, J., Poulsen, J.E.,
Ryder, L.P., Nielsen. L.S., Thomsen, M.. Svejgaard, A. (1974): HLA antigens and
diabetes mellitus. Lancet 2(7885), 864-866
15 Gamble, D.R., Kinsley, M.L., FitzGerald, M.G., Bolton. R., Taylor, K.W. (1969):
Viral antibodies in diabetes mellitus. British Medical Journal 3(671) 627-630.
16 Bottazzo, G.F., Florin-Christensen, A., Doniach, D. (1974) Islet cell antibodies in
diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2(7892) 1279-1281
and 1529-1532.
17 Lecompte (1958)
18 Gepts (1965) Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes

•

60

(14) 619-633
19 Melton. L.J., Palumbro, P.J., Chu C.P. (1983): Incidence of diabetes mellitus by
clinical type. Diabetes Care (6):75-86.
20Thorsbv, E., Ronningen K.S. (1993): Particular HLA-DQ molecules play a dominant
role in determining susceptibility or resistance to type 1 (insuline dependent) diabetes
mellitus. Diabetologia (36):371 -377.
21 Baisch. J.M., Weeks, T., Giles R., Hoover. M., Stastny. P.. Capra, J.D. (1990):
Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus.
New England Journal of Medicine (322): 1836-1841.
22 Caillat-Zuchman, S., Bertin, E., Timsit. J., Boitard, C., Bach. J.F. (1993): Protection
from insulin-dependent diabetes mellitus is linked to a peptide transporter gene. European
Journal of Immunology (23): 1784-1788.
23 Bain. S.C., Prins, J.B., Hearne. C.M., Rodrigues, NR., Rowe, B.R., Pritchard. L.E.,
Ritchie. R.J., Hall, J.R., Undlien, D.E., Ronningen. K.S., Dunger, D.B., Barnett, A.H.,
Todd. J.A. (1992): Insulin gene region-encoded susceptibility to type 1 diabetes is not
restricted to HLA-DR4-positive individuals. Nature Genet (2):212-215.
24 Millward, B.A., Welsh. K.I., Leslie R.D.G., Pyke D.A., Demaine, A.G. (1987): T cell
receptor beta chain polymorphisms are associated with insulin dependent diabetes. Clin
Exp Immunol (70). 152-157.
25 Elliot, R.B., Reddy, S.N., Bibby, N.J., Kida, K. (1988): Dietary prevention of diabetes
in the non-obese diabetic mouse. Diabetologica (31 ):62-64.
26 Oldstone, M.B., (1990): Viruses as therapeutic agents. I. Treatment of non-obese
diabetic mice with virus prevents insulin-dependent diabetes mellitus while maintaining
general immune competence. Journar of Experimental Medicine (171 ):2Q77-2089.
27 Takei, I., Asaba, Y., Kasatani, T., Maruyama, T., Watanabe, K., Yanagawa T., Saruta,
T., Ishii, T. (1992): Suppression of development of diabetes in NOD mice by lactate
dehydrogenase virus infection. Journal of Autoimmnunity (5):665-673.
28 Tajima, N., Matsushima, M., Laporte R.E. (1993): Geographical Variation In InsulinDependent Diabetes Mellitus Incidence. Pages 25-44 from "Causes of Diabetes” Edited by
Leslie. R.D.G., John Wiley & Sons Ltd.
29 Williams, A.J.K., Krug, J.P., Lampeter E.F. (1990): Raised temperature reduces the
incidence of diabetes in the NOD mouse. Diabetologia (33):635-637.
30 Patrick. S.L., Moy, C.S., Laporte. R.E. (1989): The world of insulin-dependent
diabetes mellitus: what international epidemiologic studies reveal about the etiology and
natural history of IDDM. Diabetes Metab Rev (5):571-578.
31 Bodansky, H.J., Staines, A., Stephenson, C. (1992): Evidence for an evironmental
effect in the aetiology of insulin-dependent diabetes in a transmigratory population. British
Medical Journal (304): 1020-1022.
32 Bingley, P.J., Gale, E.A.M. (1989): Rising incidence of IDDM in Europe. Diabetes Care
(12):289-295.
33 Yoon J.W., Austin, M., Onodera, T., Notkins, A.L. (1979): Virus induced diabetes
mellitus. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. New
England Journal of Medicine (300): 1173-1179.
34 Pak, C.Y., Eun, H.M., McArthur, R.G., Yoon J.W. (1988): Association of
cytomegalovirus infection with autoimmune type 1 diabetes. Lancet (ii): 1 -5.
35 Mayer E.J., Hamman, R.F., Gray, E.C. (1988): Reduced risk of IDDM among breast¬
fed children. Diabetes (37): 1625-1632.
36 Surwit, R.S., Schenider, M.S., Feinglos, M.N. (1992): Stress and diabetes mellitus.
Diabetes Care (15): 1413-1422.
37 Lernmark, A., Freedman, Z.R., Hoffmann, C., Rubernstein A.H., Steiner, D.F.,
Jackson R.L., Winter R.J., Traisman, H.S. (1978): Islet cell surface antibodies in juvenile
diabetes mellitus. New England Journal of Medicine (299)375-380.
38 Todd, J.A. (1990): Genetic control of autoimmunity in type I diabetes. Immunology

.

61

Today (11): 122-129.
39 Wicker L.S., Miller, B.J., Mullen, Y. (1986): Transfer of autoimmune diabetes mellitus
with splenocytes from nonobese diabetic (NOD) mice. Diabetes (35):855-860.
411 Sempe. P., Bedossa. P., Richard, M.F.. Villa, M.C., Bach, J.F.. Boitard, C. (1991):
Anti-alpha/beta T cell receptor monoclonal antibody provides an efficient therapy for
autoimmune diabetes in nonobese diabetic (NOD) mice. European Journal of Immunology
(21): 1163-1169.
41 Mulder. K., Colditz, EG., (1993): Migratory responses of ovine neutrophils to
inflamatory mediators in vitro and in vivo. Journal of Leukocyte Biology 53(3):273-278.
42 Allison, J., McClive, P., Oxbrow, L., Baxter, A., Morahan. G., Miller. J.F. (1994):
Genetic requirements for acceleration of diabetes in non-obese diabetic mice expressing
interleukin-2 in islet beta-cells. European Journal of Immunology 24(10): 2535-2541.
43 Nagata, M., Santamaria, P., Kawamura, T., Utsugi, T., Yoon. J.W. (1994): Evidence
for the role of CD8+ cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese
diabetic mice. Journal of Immunology. 152(4):2042-2050.
44 Pukel, C., Baquerizo, H., Rabinovitch. A. (1988): Destruction of rate islet cell
monlayers by cytokines. Synergistic interactions of interferon-gamma, tumor necrosis
factor, lymphotoxin, and interluekin 1. Diabetes (37): 133-136.
45 Rosenfeld. M.G., Mermod, J.J., Amara, S.G., Swanson. L.W., Sawchenko, P.E.,
Rivier, J., Vale. W.W.. Evans, R.M. (1983): Production of a novel neuropeptide encoded
by the calcitonin gene via tissue-specific RNA processing. Nature (304): 129-135.
46 Amara, S.G., Jonas V., Rosenfeld M.G., Ong E.S., Evans R.M., (1982): Alternative
RNA processing in calcitonin gene expression generates mRNAs encoding different
polypeptide products. Nature (298):240-244.
47 Amara, S.G., Jonas, V., O’Neil J.A., Vale, W., Rivier, J.. Roos, B.A., Evans, R.M.,
Rosenfeld, M.G. (1982): Calcitonin COOH-terminal cleavage peptide as a model for
identification of novel neuropeptides predicted by recombinant DN A analysis. Journal of
Biological Chemistry (257):2129-2132.
48 Weisenfeld-Hallen, Z., Hokfelt, T., Lundberg, J.M., Forssmann, W.C., Reinecke, M.,
Tschopp, F.A., Fischer, J.A. (1984): Immunoreactive calcitonin gene related peptide and
substance P coexist in sensory neuron to the spinal cord and interact in spinal behavioral
responses of the rat. Neuroscience Letters (52): 199-204.
49 Takami, K., Kamal, Y.. Shiosaka, S., Lee, Y., Girgis, S., Hillyard. C.J., MacIntyre,
L, Emson, P.C., Tohyama, M. (1985): Immunohistochemical evidence for the
coexistence of calcitonin gene-related peptide and choline acyltransferase-like
immunoreactivity in neurons of rat hypoglossal, facial and ambiguous nuclei. Brain
Research (328):385-389.
50 Skofitcsh, G., and Jacobowitz, D.M. (1985): Calcitonin gene-related peptide: Detailed
immunohistochemical distribution in the central nervous system. Peptides (6):721-745.
51 Stemini, C., Reeve Jr., J.R., Brecha, N. (1987) Distribution and characterization of
calcitonin gene-related peptide immunoreactivity in the digestive system of normal and
capsaicin-treated rats. Gastroenterology (93):852-862.
52 Morris H.R., Panico M., Etienne T., Tippins J., Girgis S.I., MacIntyre I., (1984):
Isolation and characterization of human calcitonin gene-related peptide. Nature.
308(5961 ):746-8.
53 Edbrooke M.R.. Parker D.. McVey J.H., Riley J.H.. Sorenson G.D.. Pettengill O.S.,
Craig R.K., (1985): Expression of the human calcitonin/CGRP gene in lung and thyroid
carcinoma. EMBO Journal. 4(3):715-24.
54 McEwan J.R., Benjamin N., Larkin S., Fuller R.W., Doliery C.T., MacIntyre I.,
(1988): Vasodilatation by calcitonin gene-related peptide and by substance P: a comparison
of their effects on resistance and capacitance vessels of human forearms. Circulation.
77(5): 1072-80.

62

55 Brain S.D., Williams T.J., (1988): Substance P regulates the vasodilator activity of
calcitonin gene-related peptide. Nature. 335(6!85):73-5.
56 New, H.V., Mudge, A.W. (1986): Calcitonin gene-related peptide regulates muscle
acetylcholine receptor synthesis. Nature (323):809-81 1.
57 Ohlen, A.. Wiklund, M.P.. Persson, M.G., Hedqvist, P. (1988): Calcitonin gene-related
peptide desensitizes skeletal muscle arterioles to substance P in vitro. British Journal of
Pharmacology (95):673-674.
58 Hughes. J.J., Levine, A.S.. Morley. J.E., Gosnell. B.A.. Silvis, S.E. (1984):
Intraventricular calcitonin gene-related peptide inhibits gastric acid secretion. Peptides
(5):665-668.
59 Brain. S.D , William. T.J., Tippins. J.R., Morris. H.R., MacIntyre, I. (1985):
Calcitonin gene-related peptide is a potent vasodilator. Nature (313):54-56.
60 Tippins J. R. (1986): CGRP: a novel neuropeptide from the calcitonin gene is the most
potent vasodilator known. Journal of Hypertension - Supplement. 4(5):S 102-5
61 Mulderry P.K., Ghatei M.A.. Rodrigo J., Allen J.M.. Rosenfeld M.G., Polak J.M.,
Bloom S.R. (1985): Calcitonin gene-related peptide in cardiovascular tissues of the rat.
Neuroscience. 14( 3 ):947-954
62 Haegerstrand A., Dalsgaard C.J., Jonzon B.. Larsson O., Nilsson J., (1990):
Calcitonin gene-related peptide stimulates proliferation of human endothelial cells.
Proceedings of the National Academy of Sciences of the United States of America.
87(9):3299-303.
63 Tshikawa. T., Okamura, N.. Saito. A.. Masaki. T., Goto, K. (1988): Positive inotropic
effect of calcitonin gene-related peptide (CGRP) mediated by cyclic .AMP in the guinea pig
heart. Circulation Research (63):726-734.
64 Grunditz, T., Ekman, R., Hakanson, R.., Rerup, C., Sundler, F., Uddman, R. (1986):
Calcitonin gene-related peptide in thyroid nerve fibers and C cells: Effects on thyroid
hormone secretion and response to hypercalcemia. Endocrinology (119):2313-2324.
65 Hermansen. K., Ahren, B. (1990): Dual effects of calcitonin gene-related peptide on
insulin secretion in th perfused dog pancreas. Reg. Peptides (27): 147-149.
66 Krahn, D.D.. Gosnell, B.A., Levine, A.S., Morley, J.E. (1984): Effects of calcitonin
gene-related peptide on food intake. Peptides (5):861 -864.
67 Wang F., Millet I., Bottomly K., Vignery A., (1992): Calcitonin gene-related peptide
inhibits interleukin 2 production by murine T lymphocytes. Journal of Biological
Chemistry. 267(29):21052-7.
68 Leiter, E.H., Serreze, D.V., Prochazka. M. (1990): Genetics and epidemiology of
diabetes in NOD mice. Immunology Today (11): 147-149.
69 Elias, D, (1994): The NOD Mouse: A Model for Autoimmune Insulin-Dependent
Diabetes, from “Autoimmune Disease Models" by Academic Press, Inc.
70 Bedossa, P., Thivolet, C., Bendelac, A., Bach, J.F., Carnaud, C. (1991): Journal of
Immunology (146):85-88.
71 Michel, C., Boitard. C.. Bach. J.F. (1988): Diabetologia (31): 322-328.
72 Atkinson, M.A.. Maclaren, N.K. (1988): Autoantibodies in nonobese diabetic mice
immunoprecipitate 64,000-Mr islet antigen. Diabetes (37): 1587-1590.
73 Elias, D., Markovits, D., Reshef, T., van-Der Zee, R., Cohen, I.R. (1990): Induction
and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65kDa heat shock protein. Proc. Natl. Acad. Sci. USA. (87): 1576-1580.
74 Acha-Orbea, H., McDevitt, H O. (1987): The first external domain of the nonobese
diabetic mouse class III-A 13 chain is unique. Proc. Natl. Acad. Sci. USA (1984):24352439.
75 Lund, T., O’Reilly. L., Hutchings, P.. Kanagawa, O., Simpson. E., Gravely, R..
Chandler, P., Dyson, J., Picard. J.K., Edwards, A., Kioussis, D., Cooke, A. (1990):
Prevention of insulin dependent diabetes mellitus in non-obese diabetic mice by transgenes

'

63

encoding modified I-A 13-chain or normal I-E alpha-chain. Nature (345):727-729.
76 Podolin. P.L.. Pressey, A., DeLarato, N.H., Fischer, P.A., Peterson, L.B., Wicker,
L.S. (1993): I-E+ nonobese diabetic mice develop insuiitis and diabetes. J. Exp. Med.
(178 ):793-803.
77 Lomedico, P., Rosenthal, N., Efstratiadis, A., Gilbert, W., Kolonder, R., Tizard, R.
(1979): The structure and evolution of the two non-allelic rat preproinsulin genes. Cell
(18):545-558.
78 Sambrook J., Fritsch E.F., Maniatis T., (1989): “Molecular Cloning: A Laboratory
Manual,” Cold Spring Harbor Laboratory Press, Plainvievv, New York.
79Hogan, B., Constantini, F., & Lacy, E. (1986). in Manipulating the mouse embryo: A
laboratoy manual (Cold spring Harbor Lab., Cold Spring Harbor, NY)
80 Cohen, J. (1988). Statistical pow'er analysis for behavior sciences. (2nd Ed, Hillsdale.
N.J., Erlbaum associates), p. 567.
81 Picarella, D.E., Kratz, A., Li, C.B., Ruddle, N., Flavell, R.A. (1992): Proc. Natl.
Acad. Sci. USA (89): 10036-10040.
82 Lo, D., Burkly, L.C., Widera, G., Cowing, C., Flavell. R. A., Palmiter, R. D., &
Brinster, R.L. (1988): Cell. (52): 159-68
83 Pozzilli, P., Signore, A., Williams, A., & Philip, B. (1993): Immunol. Today (14):
193-196
84 Jamarillo, A., Gill, B., & Delovitch. T. (1994): Life Science (55): 1163-1177
85 Kanazawa, Y., Komeda, K., Sato, S.. Mon. S., Akanuma, K., & Takaku, F. (1984):
Diabetologia (27): 113-115
86 Signore, A., Pozzilli, P., Gale, E., Andreani, D., & Beverley, P. (19891).
Diabetologia (32): 282-289
87Trembleau, S., Penna, G., Bosi, E., Mortara, A., Gately, M. K., Adorinin, L. (1995):
J. Exp. med. (181): 817821
88 Hosoi, J., Murphy, G. F., Egan, C. L., Lerner. E. A., Grabbe, S., Asahina. A. &
Granstein, R. D. (1993): Nature (363): 159-163
89 Bach, J-F. (1994): Endocr. Rev. (15): 516-542
90Rapoport, M. J., Jaramillo, A., Zipris, D., Lazarus, A. H., Serreze, D. V., Leiter, E.
H„ Cyopick, P„ Danska, J. S„ & Delovitch, T. L. (1993): J Exp Med. (178): 87-99
91 Umeda, Y., & Arisawa. M. (1989): Inhibition of natural killer activity by calcitonin
gene-related peptide. Immunopharm. Immunotox. (11): 309-320
92 Nong, Y.H., Titus, R.G., Ribeiro, J.M., & Remold, H.G. (1989). J Immun. (143):
45-49
93 Vignery, A., Wang, F., & Ganz, M. B. (1991). J. Cellular Physiology. (149): 301 306
94 Levy-Marchal, C., Czemichiow, P. (1992): “Epidemiology and Etiology of Insulin
Dependent Diabetes in the Young.” Karger Press, Basel, Switzerland.
95 Leslie. R.D.G. (1993): “Causes of Diabetes: Genetic and Evirvonmental Factors,” John
Wiley and Sons. New York.
96 Gupta, S. (1984): “Immunology of Clinical and Experimental Diabetes.” Plenum
Publishing, New York.
97 Coutinho, A., Kazatchkine. D. (1994): “Autoimmunity: Physiology and Disease.” John
Wiley and Sons, New York.

YALE MEDICAL LIBRARY

3 9002 08676 0 30

HARVEY CUSHING / JOHN HAY WHITNEY
MEDICAL LIBRARY
MANUSCRIPT THESES

Unpublished theses submitted for the Master's and Doctor's degrees and
deposited in the Medical Library are to be used only with due regard to the
rights of the authors.
Bibliographical references may be noted, but passages
must not be copied without permission of the authors, and without proper credit
being given in subsequent written or published work.

This thesis by
has been
used by the following persons, whose signatures attest their acceptance of the
above restrictions.

NAME AND ADDRESS

DATE

